See whether Helium helps you make better-informed decisions. Try every Pro Trader feature for 30 days. No credit card required.
Try every Pro Trader feature for 30 days. No credit card required.
Promotional framing from Agenus highlights encouraging BOT+BAL activity in post-immunotherapy hepatocellular carcinoma, citing ORR 17%, 18-week CBR 50%, and mOS 12.3 months in a small 18-evaluable cohort, while noting safety signals and limitations for future validation, reflecting pro-company bias with standard risk disclosures.
Phase 1b expansion cohort in hepatocellular carcinoma after prior immunotherapy shows encouraging efficacy signals and a manageable safety profile, based on 19 patients across six U.S. sites (18 efficacy-evaluable).
2026 © Helium Trades
Privacy Policy & Disclosure
* Disclaimer: Nothing on this website constitutes investment advice, performance data or any recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. Helium Trades is not responsible in any way for the accuracy
of any model predictions or price data. Any mention of a particular security and related prediction data is not a recommendation to buy or sell that security. Investments in securities involve the risk of loss. Past performance is no guarantee of future results. Helium Trades is not responsible for any of your investment decisions,
you should consult a financial expert before engaging in any transaction.
